Regenerative medicine, according to the US National Institutes of Health (NIH), is the process of developing functional tissues for the repair and/or replacement of damaged organs or tissues. Having lost function due to disease, congenital defects, and age, these tissues or organs are regenerated to establish and restore normal function.
Regenerative medicine is used in a wide range of applications including neurology, musculoskeletal, cardiovascular, and orthopedic. Earlier this month, a study showed that a new regenerative medicine appears to relieve eye pain, light sensitivity, and burning, and stimulate faster tissue repair following eye surgery. Findings by a team of researchers in Turkey suggest that this new compound can be beneficial for all those patients who undergo refractive surgery and corneal implants.
Demand for Tissue Engineering to Rise amid High Cost of Biomaterials
Regenerative medicine is an emerging branch of medical science and is being extensively used to treat cardiovascular disease, musculoskeletal disease, and orthopedic disorders. The growing prevalence of bone and joint disorders and the rise in orthopedic surgeries have fuelled the demand for regenerative medicines. Furthermore, technological innovations in stem cell therapy, biomaterials, and tissue engineering have supported the growth of the global regenerative medicines market. However, regulatory constraints pose a threat to the development of regenerative medicines. “Ethical issues related to allogeneic bone grafts and stem cell therapy, and post implantation infections are impeding the growth of the overall market,” the analyst states.
Technology has played a pivotal part in the success of regenerative medicines. Favorable reimbursement policies had augmented the demand for biomaterials in 2012. However, tissue engineering is being increasingly preferred over biomaterials. In fact, during the period between 2013 and 2019, tissue engineering is anticipated to expand at the fastest pace. “The high cost of biomaterials has led to their decreased adoption among patients,” the analyst mentions.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=419
The global regenerative medicine market is anticipated to expand at a CAGR of 12.8% during the period between 2013 and 2019. The overall market stood at a valuation of US$2.6 bn in 2012 and is projected to be worth US$6.5 bn by 2019.
Global Regenerative Medicine Market: Geographical Segmentation
Regionally, North America is the key contributor to the global regenerative medicine market due to the presence of several leading market players in the region, which has led to the latest advances in the field becoming easily available to patients. The well-funded R&D environment in the U.S. is also a key driver for the North America bone and joint regenerative medicine market, which is likely to remain a dominant regional market for regenerative medicine in the coming years.
Asia Pacific is likely to emerge as a leading regional market for bone and joint regenerative medicine in the coming years. The increasing patient pool of bone and joint conditions and the steady rise in healthcare expenditure in Asia Pacific are vital in ensuring sustained growth of the Asia Pacific regenerative medicine market in the coming years. Many key multinational players in the regenerative medicine market have identified Asia Pacific as a high-potential market for the future and have accordingly taken steps to expand their presence in the region.
Key players examined in the report include Smith & Nephew plc, Anika Therapeutics Inc., DePuy Synthes Inc., Baxter International Inc., Stryker Corporation, Medtronic Inc., Arthrex Inc., Zimmer Holdings Inc., and CONMED Corporation.